Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans
New York, Jan 14, 2026, 14:09 EST — Regular session Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end. This matters since Nuvalent remains a clinical-stage company. Investors want a clearer timeline for its first possible U.S. product launch and some indication it won’t need to raise capital again anytime soon. Nuvalent’s update sets a firm deadline for the next major catalyst: the U.S. Food and Drug Administration’s decision timeline on its first potential approval, a move
